People usually search for this
Adipotide 5mg
$60.00
≥99% purity · HPLC verified · MS confirmed
How we test →
Products will arrive in a lyophilized (powder) form for maximum stability
Adipotide is a chimeric peptide combining a prohibitin-targeting homing sequence with a pro-apoptotic component, designed to selectively reduce adipose tissue vasculature. Preclinical primate and rodent studies documented fat mass reductions, with renal toxicity observed at higher doses limiting human research. Supplied as a 5mg lyophilized vial at ≥99% HPLC purity, for research use only.
Volume discounts
Auto-applied at checkout
Free shipping on orders of $200+
Compound Identity
COMPOUND NAME
Adipotide
SYNONYMS
CKGGRAKDC-GG-D(KLAKLAK)?, Prohibitin-targeting proapoptotic peptide, 859216-15-2, HKPao, EX-A6186, DA-74204
CAS NUMBER
859216-15-2
MOLECULAR FORMULA
C111H206N36O28S2
MOLECULAR WEIGHT
~2557.2 g/mol
STRUCTURE
Disulfide-bridged cyclic peptide (CKGGRAKDC) linked via glycine-glycine to a proteolysis-resistant amphipathic D-enantiomeric proapoptotic motif D(KLAKLAK)?
PEPTIDE SEQUENCE
H-Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys-Gly-Gly-D-Lys-D-Leu-D-Ala-D-Lys-D-Leu-D-Ala-D-Lys-D-Lys-D-Leu-D-Ala-D-Lys-D-Leu-D-Ala-D-Lys-OH
CHEMICAL STRUCTURE
Molecular Formula: C111H206N36O28S2
Source: PubChem
Mechanism of Action
Adipotide functions by selectively targeting the prohibitin receptor on endothelial cells within white adipose tissue vasculature via its CKGGRAKDC motif. Upon binding, the conjugated D(KLAKLAK)? domain is internalized into the cells, where it disrupts mitochondrial membranes, triggering targeted apoptosis of the vasculature. This results in a collapse of blood supply to white adipose tissue, leading to fat resorption and reduction in adipose mass without affecting other tissues or relying on central appetite regulation pathways1-4.
Biological Activity
In vivo studies demonstrate that Adipotide induces pronounced and rapid weight loss in rodent and primate models of obesity by selectively ablating the vasculature of white fat. This effect reduces total body fat, improves insulin sensitivity, decreases serum leptin, and reverses diet-induced or genetic obesity, all with a generally reversible and predictable renal side effect profile and no evidence of visceral illness or malabsorption1-4.
Storage
- Store at –20°C, protected from light. Reconstituted solution should be aliquoted and stored at –20°C and used within 2 weeks.
Drug Categories
Experimental anti-obesity agent, Peptidomimetic, Angiogenesis inhibitor
Additional Notes
- Not approved for clinical use in humans; for research purposes only.
- Designed for maximized selectivity to white adipose vasculature.
Summary Table
Property
Description
CAS Number
859216-15-2
Molecular Formula
C111H206N36O28S2
Molecular Weight (MW)
~2557.2 g/mol
Mechanism of Action
Targets prohibitin on white adipose tissue endothelium, induces apoptosis
Biological Activity
Rapid, selective adipose reduction; improves insulin sensitivity
Supplied Form
Lyophilized powder
Purity
≥95% (HPLC)
Storage
–20°C, light protected, aliquot after reconstitution
Drug Categories
Experimental anti-obesity; peptide angiogenesis inhibitor
Additional Notes
For research only; not for human/veterinary drug use
Disclaimer
For Research Use Only. Not intended for human or veterinary use. This compound is supplied solely for laboratory and R&D purposes.
Detailed Product Description
Preclinical studies in rodent and nonhuman primate models have shown that Adipotide administration results in striking weight loss, robust reduction of visceral and subcutaneous adipose tissue, and significant improvements in insulin resistance—all without the adverse neuropsychiatric or gastrointestinal effects that limit current obesity drugs. The compound’s effects are obesity-specific in primates: lean animals show minimal response, highlighting specificity for pathological adipose tissue. Renal toxicity, characterized by reversible tubular injury, is the main dose-limiting side effect observed in primate studies; other metabolic parameters such as lipid profiles remain stable during treatment
Research Highlights
Selectively targets adipose endothelial cells via prohibitin-binding CKGGRAKDC motif1.
Delivers proapoptotic D(KLAKLAK)
? peptide, disrupting mitochondrial function and triggering apoptosis2.
Induces rapid, significant weight and fat loss in rodent and primate obesity models, with average reductions of 30–40% body fat3.
Improves insulin sensitivity and reduces serum insulin and leptin levels, with no detectable adverse effects on engagement of appetite or malabsorption4.
Prohibitin Receptor Binding (CKGGRAKDC motif)
- Highly specific binding to prohibitin expressed on the surface of endothelial cells in white adipose tissue, allowing selective targeting and internalization of the linked peptide cargo1.
Mitochondria-Targeted Apoptosis [D(KLAKLAK)
? domain]
- After binding and uptake, the D(KLAKLAK)? sequence disrupts mitochondrial membranes, activating intrinsic apoptotic cascades and specifically inducing death of the adipose endothelial cell, leading to regression of the supporting vasculature and resorption of fat2-4.
Physiological/Systemic Outcomes
- Fat loss is achieved through degeneration of the white fat blood supply, resulting in reduced adiposity, decreased insulin resistance, and improved metabolic profiles1.
- Minimal to no effect on CNS appetite-regulation circuits, preserving food intake regulatory feedback and limiting off-target adverse effects2.
- Effect selective for obese (not lean) animals in primate models4.
Pharmacokinetic Profile
Route of Administration
Subcutaneous
Dosing Frequency
Daily
- Route of Administration: Subcutaneous injection (in animal models)
- Dosing Frequency: Daily, but duration depends on study design
- Half-Life: Not formally established in humans
Formulation & Handling
- Lyophilized powder, reconstitute with sterile buffer
- Use within indicated stability window after reconstitution
- Protect from light, store at –20°C
Selected Clinical Trial Activity
Adipotide is a research-grade compound that has been studied in laboratory settings but has not undergone full clinical development. It is not approved for therapeutic use in humans, and no large-scale clinical trials have been conducted to evaluate its safety or efficacy as a medication. Adipotide is supplied strictly for laboratory research and investigational purposes only.
References
1
Kolonin, M.G., Saha, P.K., Chan, L., Pasqualini, R. & Arap, W. Reversal of obesity by targeted ablation of adipose tissue. Nat. Med. 10, 625–632 (2004).
2
Barnhart, K.F. et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci. Transl. Med. 3, 108ra112 (2011).
3
Kim, D.H. et al. Attenuation of obesity by an adipocyte-targeting peptide in mice and monkeys. Diabetes 59, 907–915 (2010).
4
Arap, W., Kolonin, M.G., Trepel, M., Lahdenranta, J., Cardó-Vila, M., Giordano, R.J. et al. Steps toward mapping the human vasculature by phage display. Nat. Med. 8, 121–127 (2002).
Quality & Purity
This product is synthesized via solid-phase peptide synthesis (SPPS) and tested to ≥99% purity by HPLC with identity confirmed by mass spectrometry. A Certificate of Analysis (COA) is available for every batch. Learn about our full quality and testing process →
Related Products
Bioregulators
Vesugen 20mg
$70.00
Read more 
Exercise
MOTS-C 40mg
$200.00
Add to cart 
GHRP
Tesamorelin 20mg
$200.00
Add to cart Related products
BPC-157 5mg
Summary Description: BPC-157 is a synthetic pentadecapeptide corresponding to a partial sequence of a protein found in human gastric juice. In preclinical models, it has demonstrated pro-angiogenic, cytoprotective, and anti-inflammatory properties1-3. BPC-157 accelerates tissue repair across tendon, ligament, muscle, and epithelial models by modulating nitric oxide pathways, upregulating VEGF and other growth factors, and promoting fibroblast migration4. Its chemical stability in gastric environments and efficacy across multiple administration routes make it a candidate for further investigation in regenerative pharmacology2.
Products will arrive in a lyophilized (powder) form for maximum stability
GLP-1 5mg
Summary Description: Semaglutide is a synthetic, long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) used primarily for the treatment of type 2 diabetes and, at higher doses, for chronic weight management in adults with overweight or obesity. It mimics endogenous GLP-1, enhancing glucose-dependent insulin secretion, decreasing glucagon secretion, and significantly reducing appetite and energy intake, which leads to clinically meaningful weight loss. Structurally, semaglutide is a modified peptide analog of human GLP-1, designed to resist enzymatic degradation and prolong its biological half-life, allowing for once-weekly subcutaneous injection.
Products will arrive in a lyophilized (powder) form for maximum stability
PT-141 10mg
Summary Description: PT-141 is a synthetic cyclic heptapeptide derivative of alpha-melanocyte stimulating hormone (?-MSH), designed to act as a potent and selective melanocortin receptor agonist, particularly at MC3 and MC4. It is primarily researched for its unique ability to induce sexual arousal and enhance sexual function in both men and women without acting via direct hormonal or vascular mechanisms. PT-141 is supplied strictly for laboratory research use1,2,4.
Products will arrive in a lyophilized (powder) form for maximum stability
Retatrutide 10mg
Summary Description: Retatrutide is a next-generation investigational medication initially developed for the treatment of obesity and type 2 diabetes, with emerging evidence highlighting its potential multi-system benefits. Retatrutide is a synthetic peptide based on a glucose-dependent insulinotropic polypeptide (GIP) backbone, but uniquely, it functions as a triple agonist. This means it simultaneously activates the receptors for GIP, glucagon-like peptide-1 (GLP-1), and glucagon. Through this triple-receptor agonism, retatrutide not only lowers blood glucose levels and enhances insulin sensitivity but also suppresses appetite, increases energy expenditure, and reduces body weight. Early clinical studies suggest that retatrutide may improve cardiometabolic profiles by reducing blood pressure and improving lipid levels, further underscoring its promise for addressing both metabolic and cardiovascular risk factors in individuals with obesity and diabetes.
Products will arrive in a lyophilized (powder) form for maximum stability
SS-31 50mg
Summary Description: SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that binds selectively to cardiolipin in the inner mitochondrial membrane. It acts as a mitochondrial protective agent, stabilizing mitochondrial structure, enhancing oxidative phosphorylation, reducing production of reactive oxygen species (ROS), and mitigating cellular damage in diverse models of mitochondrial dysfunction. Owing to its unique structure and mode of action, SS-31 demonstrates potential therapeutic value across cardiovascular diseases, neurodegenerative disorders, kidney injury, and myopathies associated with mitochondrial dysfunction1-6.
Products will arrive in a lyophilized (powder) form for maximum stability
Tirzepatide 10mg
Summary Description: Tirzepatide is a novel, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist designed for the treatment of type 2 diabetes and obesity. Engineered as a synthetic peptide based on the native GIP sequence and modified for extended half-life via fatty acid conjugation, tirzepatide delivers glycemic control, profound weight loss, and cardiometabolic benefits. Its imbalanced receptor affinity and biased signaling provide enhanced insulin secretion and improved metabolic outcomes beyond selective GLP-1 agonism.1,3,4
Products will arrive in a lyophilized (powder) form for maximum stability
Tirzepatide 15mg
Summary Description: Tirzepatide is a novel, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist designed for the treatment of type 2 diabetes and obesity. Engineered as a synthetic peptide based on the native GIP sequence and modified for extended half-life via fatty acid conjugation, tirzepatide delivers glycemic control, profound weight loss, and cardiometabolic benefits. Its imbalanced receptor affinity and biased signaling provide enhanced insulin secretion and improved metabolic outcomes beyond selective GLP-1 agonism.1,3,4
Products will arrive in a lyophilized (powder) form for maximum stability